These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 31668839)

  • 1. Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16).
    Park I; Kim BS; Lim HY; Kim HJ; Lee HJ; Choi YJ; Park KH; Lee KH; Yoon S; Hong B; Hong JH; Ahn H; Lee JL
    Eur J Cancer; 2020 Mar; 127():183-190. PubMed ID: 31668839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM).
    Holmsten K; Jensen NV; Mouritsen LS; Jonsson E; Mellnert C; Agerbæk M; Nilsson C; Moe M; Carus A; Öfverholm E; Lahdenperä O; Brandberg Y; Johansson H; Hellström M; Maase HV; Pappot H; Ullén A
    Eur J Cancer; 2020 Mar; 127():173-182. PubMed ID: 31648851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine/nab-paclitaxel vs gemcitabine/carboplatin for advanced urothelial carcinoma.
    An X; Xue C; Chen M; Ni M; Ma H; Tian L; Huang R; Li X; Ye Y; Qin T; Dong P; Li Z; Peng J; Yao K; Zhou F; Liu Z; Shi Y
    BJU Int; 2024 Jul; 134(1):63-71. PubMed ID: 38009394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial.
    Kim ST; Kang JH; Lee J; Lee HW; Oh SY; Jang JS; Lee MA; Sohn BS; Yoon SY; Choi HJ; Hong JH; Kim MJ; Kim S; Park YS; Park JO; Lim HY
    Ann Oncol; 2019 May; 30(5):788-795. PubMed ID: 30785198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer.
    Weissman CH; Reynolds CH; Neubauer MA; Pritchard S; Kobina S; Asmar L
    J Thorac Oncol; 2011 Feb; 6(2):358-64. PubMed ID: 21206386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
    Fiteni F; Jary M; Monnien F; Nguyen T; Beohou E; Demarchi M; Dobi E; Fein F; Cleau D; Fratté S; Nerich V; Bonnetain F; Pivot X; Borg C; Kim S
    BMC Gastroenterol; 2014 Aug; 14():143. PubMed ID: 25117717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.
    De Santis M; Bellmunt J; Mead G; Kerst JM; Leahy M; Maroto P; Gil T; Marreaud S; Daugaard G; Skoneczna I; Collette S; Lorent J; de Wit R; Sylvester R
    J Clin Oncol; 2012 Jan; 30(2):191-9. PubMed ID: 22162575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine plus split-dose cisplatin could be a promising alternative to gemcitabine plus carboplatin for cisplatin-unfit patients with advanced urothelial carcinoma.
    Kim YR; Lee JL; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):141-53. PubMed ID: 26001531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.
    Balar AV; Apolo AB; Ostrovnaya I; Mironov S; Iasonos A; Trout A; Regazzi AM; Garcia-Grossman IR; Gallagher DJ; Milowsky MI; Bajorin DF
    J Clin Oncol; 2013 Feb; 31(6):724-30. PubMed ID: 23341513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules.
    Taïeb J; Bonyhay L; Golli L; Ducreux M; Boleslawski E; Tigaud JM; de Baere T; Mansourbakht T; Delgado MA; Hannoun L; Poynard T; Boige V
    Cancer; 2003 Dec; 98(12):2664-70. PubMed ID: 14669287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract.
    Theodore C; Bidault F; Bouvet-Forteau N; Abdelatif M; Fizazi K; di Palma M; Wibault P; de Crevoisier R; Laplanche A
    Ann Oncol; 2006 Jun; 17(6):990-4. PubMed ID: 16600984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653).
    Sadeghi S; Groshen SG; Tsao-Wei DD; Parikh R; Mortazavi A; Dorff TB; Kefauver C; Hoimes C; Doyle L; Quinn DI; Newman E; Lara PN
    J Clin Oncol; 2019 Oct; 37(29):2682-2688. PubMed ID: 31390274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial.
    García-Donas J; Font A; Pérez-Valderrama B; Virizuela JA; Climent MÁ; Hernando-Polo S; Arranz JÁ; Del Mar Llorente M; Lainez N; Villa-Guzmán JC; Mellado B; González Del Alba A; Castellano D; Gallardo E; Anido U; García Del Muro X; Domènech M; Puente J; Morales-Barrera R; Pérez-Gracia JL; Bellmunt J
    Lancet Oncol; 2017 May; 18(5):672-681a. PubMed ID: 28389316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: report of efficacy, quality of life and geriatric assessment.
    Bamias A; Lainakis G; Kastritis E; Antoniou N; Alivizatos G; Koureas A; Chrisofos M; Skolarikos A; Karayiotis E; Dimopoulos MA
    Oncology; 2007; 73(5-6):290-7. PubMed ID: 18477854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma.
    Tsuruta H; Inoue T; Narita S; Horikawa Y; Saito M; Obara T; Numakura K; Maita S; Satoh S; Tsuchiya N; Habuchi T
    Int J Clin Oncol; 2011 Oct; 16(5):533-8. PubMed ID: 21431341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.
    De Santis M; Bellmunt J; Mead G; Kerst JM; Leahy M; Maroto P; Skoneczna I; Marreaud S; de Wit R; Sylvester R
    J Clin Oncol; 2009 Nov; 27(33):5634-9. PubMed ID: 19786668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05).
    Krege S; Rexer H; vom Dorp F; de Geeter P; Klotz T; Retz M; Heidenreich A; Kühn M; Kamradt J; Feyerabend S; Wülfing C; Zastrow S; Albers P; Hakenberg O; Roigas J; Fenner M; Heinzer H; Schrader M
    BJU Int; 2014 Mar; 113(3):429-36. PubMed ID: 24053564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
    Louvet C; Labianca R; Hammel P; Lledo G; Zampino MG; André T; Zaniboni A; Ducreux M; Aitini E; Taïeb J; Faroux R; Lepere C; de Gramont A; ;
    J Clin Oncol; 2005 May; 23(15):3509-16. PubMed ID: 15908661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin.
    Jones R; Crabb S; Chester J; Elliott T; Huddart R; Birtle A; Evans L; Lester J; Jagdev S; Casbard A; Huang C; Madden TA; Griffiths G
    BJU Int; 2020 Aug; 126(2):292-299. PubMed ID: 32336008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy.
    Nogué-Aliguer M; Carles J; Arrivi A; Juan O; Alonso L; Font A; Mellado B; Garrido P; Sáenz A;
    Cancer; 2003 May; 97(9):2180-6. PubMed ID: 12712469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.